0000000000150305

AUTHOR

Evelyn Acuña-cruz

showing 3 related works from this author

Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy…

2020

Anthracycline uptake could be affected by influx and efflux transporters in acute myeloid leukemia (AML). Combinations of single-nucleotide polymorphisms (SNPs) of wild-type genotype of influx transporters (SLC22A16, SLCO1B1) and homozygous variant genotypes of ABC polymorphisms (ABCB1, ABCC1, ABCC2, ABCG2) were evaluated in 225 adult de novo AML patients. No differences in complete remission were reported, but higher induction death was observed with combinations of SLCO1B1 rs4149056 and ABCB1 (triple variant haplotype, rs1128503), previously associated with ABCB1 and SLCO1B1 SNPs. Several combinations of SLCO1B1 and SLC22A16 with ABCB1 SNPs were associated with higher toxicities, includin…

AdultCancer ResearchGenotypeAnthracyclineSingle-nucleotide polymorphismPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineMucositisHumansMedicineIdarubicinAnthracyclinesProspective StudiesbiologyLiver-Specific Organic Anion Transporter 1business.industryHaplotypeInduction chemotherapyMyeloid leukemiaInduction ChemotherapyHematologymedicine.diseaseMultidrug Resistance-Associated Protein 2Leukemia Myeloid AcuteOncology030220 oncology & carcinogenesisbiology.proteinCancer researchATP-Binding Cassette TransportersbusinessSLCO1B1030215 immunologymedicine.drugLeukemia & Lymphoma
researchProduct

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.

2021

We have analyzed treatment patterns and outcomes of relapsed/refractory(R/R) FLT3mut AML adult patients registered in our institutional data base between 1998 and 2018. Overall, 147 patients were evaluable: 34 from 1998 to 2009, 113 from 2010 to 2018. Salvage treatments were intensive chemotherapy ( n = 25, 74%), and supportive care ( n = 9, 26%) in the 1998-2009 period, and intensive chemotherapy ( n = 63, 56%), hypomethylating agent ( n = 7, 6%), low-dose cytarabine-based ( n = 8, 7%), clinical trial ( n = 16, 14%) and supportive care ( n = 19, 17%) in the 2010-2018 period. Complete remission (CR) or with incomplete recovery (CRi) rate was 44%, 49% among patients treated intensively (vs 3…

OncologyAdultCancer Researchmedicine.medical_specialtyreal-world*real-world03 medical and health sciences0302 clinical medicineRefractoryInternal medicineAntineoplastic Combined Chemotherapy Protocolsmedicine*FLT3mut AMLHumansPatterns of carerelapseSalvage TherapyAdult patientsFLT3mut AMLbusiness.industryFLT3mut AML real-world relapse/refractoryRemission InductionCytarabineMyeloid leukemiaHematology*relapse/refractoryrefractoryLeukemia Myeloid AcuteTreatment OutcomeOncologyfms-Like Tyrosine Kinase 3030220 oncology & carcinogenesisRelapsed refractorybusiness030215 immunologyLeukemialymphoma
researchProduct

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia

2021

Objectives Genetic variability in anthracycline metabolism could modify the response and safety of acute myeloid leukemia (AML) induction. Methods Polymorphisms in genes that encodes enzymes of anthracyclines metabolic pathway (CBR3: rs1056892, rs8133052, NQO1: rs1800566, NQO2: rs1143684, NOS3: rs1799983, rs2070744) were evaluated in 225 adult de novo AML patients. Results The variant CBR3 rs8133052 was associated with lower hepatotoxicity (P = 0.028). Wild-type genotype of NQO2 rs1143684 was related to higher complete remission (P = 0.014), and the variant allele with greater gastrointestinal toxicity (P = 0.024). However, the variant genotype of NQO1 rs1800566 was associated with mucositi…

Adult0301 basic medicineAnthracycline030226 pharmacology & pharmacyNephrotoxicity03 medical and health sciences0302 clinical medicineGenotypeGeneticsmedicineMucositisHumansIdarubicinAnthracyclinesGenetic variabilityGeneral Pharmacology Toxicology and PharmaceuticsMolecular BiologyAllelesGenetics (clinical)Polymorphism Geneticbusiness.industryInduction chemotherapyMyeloid leukemiaInduction Chemotherapymedicine.diseaseLeukemia Myeloid Acute030104 developmental biologyCancer researchMolecular Medicinebusinessmedicine.drugPharmacogenetics and Genomics
researchProduct